LASA6.82

Lasa Supergenerics Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersMANGALAMBIOFILCHEMORTINGLOBEVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹34.2 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations104.3142.425.16.4
Other Income0.15.00.20.2
Total Income104.4147.525.36.5
Expenses
+ Cost of Materials Consumed79.3108.119.16.6
+ Changes in Inventories-4.1-1.94.73.4
+ Employee Benefit Expense6.36.12.21.2
+ Finance Costs1.92.70.40.5
+ Depreciation & Amortisation10.712.36.06.0
+ Other Expenses20.623.927.53.9
Total Expenses114.8151.259.921.6
EBITDA2.26.3-28.4-8.7
EBIT-8.5-6.0-34.4-14.7
Profit
PBT before Exceptional Items-10.3-3.7-34.6-15.1
+ Exceptional Items-8.8-15.70.0-0.5
Pretax Income-19.1-19.4-34.6-15.5
+ Deferred Tax2.6-4.6-0.51.0
Tax Expense2.6-4.6-0.51.0
Net Income-21.7-14.8-34.1-16.5
+ Net Income — Continuing Ops-21.7-14.8-34.1-16.5
+ Other Comprehensive Income0.10.00.00.0
Total Comprehensive Income-21.6-14.7-34.1-16.5
Per Share
Basic EPS-4.34-2.95-6.80-1.88
Diluted EPS-4.34-2.95-6.80-1.88
Other Comprehensive Income — detail
+ Other Comprehensive Income0.0
+ Items NOT to be Reclassified to P&L0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations-4.34-2.95-6.80-1.37
Diluted EPS — Continuing Operations-4.34-2.95-6.80-1.37
Basic EPS — Discontinued Operations0.000.000.00-0.51
Diluted EPS — Discontinued Operations0.000.000.00-0.51
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit29.136.31.3-3.6
Gross Margin %27.9125.465.16-57.16
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-10.3-3.7-34.6-15.1
− Exceptional Items (reconciliation)-8.8-15.70.0-0.5
Net Income Adj (tax-effected)-13.0-2.8-34.1-16.1
EPS Adj-2.59-0.57-6.80-1.83
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital50.150.150.150.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.